Loading organizations...

§ Private Profile · 8285 El Rio Street Suite 150, Houston, Texas 77030
Vapogenix is a technology company.
Vapogenix develops a novel class of non-opioid pain therapies, offering rapid-onset, long-lasting localized relief. Its innovation centers on proprietary topical formulations of volatile anesthetics, engineered to precisely target pain at its source. These treatments, currently in clinical development, aim to provide effective pain management without the systemic risks of traditional opioid medications.
Danguole Altman co-founded Vapogenix, leveraging her healthcare entrepreneurship to address unmet pain management needs. The foundational insight involved reformulating existing volatile anesthetics for topical application, enabling rapid absorption through the skin. This delivers potent, localized analgesic effects, offering a differentiated approach to pain relief.
The company targets patients needing effective localized pain management, seeking non-narcotic alternatives. Vapogenix’s vision is to transform pain care by pioneering new analgesics that provide powerful, targeted relief, mitigating societal challenges of opioid dependence. Their focus remains on advancing these solutions.
Vapogenix has raised $19.8M across 4 funding rounds.
Vapogenix has raised $19.8M in total across 4 funding rounds.
Vapogenix has raised $19.8M in total across 4 funding rounds.
Vapogenix's investors include National Institute of Arthritis and Musculoskeletal and Skin Diseases, Pamoja Capital, Green Park & Golf Ventures, Vitalize Venture Group.
Vapogenix is a Houston-based biotechnology startup developing a new class of topical analgesics derived from volatile anesthetics, targeting localized pain without systemic side effects.[1][2] The company serves patients with acute pain from wounds, burns, minor procedures, and musculoskeletal issues, addressing the limitations of traditional oral or injected painkillers that affect the entire body by offering rapid, site-specific relief—such as penetration through skin in five minutes via patches or liquids.[1][2] Its pipeline includes clinical-stage products like AWARD for wound pain in ulcers, burns, and trauma; RAFT for quick analgesia on intact skin prior to procedures like venous access; and TAIM for inflammatory and muscular pain, with preclinical efforts in postherpetic neuralgia.[3][4] As a product-in-development stage company with 6 employees, Vapogenix shows growth momentum through a $10M Series C raise in 2016 to advance clinical trials and commercialization, supported by strategic advisors and partnerships.[2][3]
Vapogenix emerged from the novel discovery that formulated volatile anesthetics—typically vaporized for surgical use—produce reversible, localized analgesic effects when applied topically.[1][2] Founded in Houston, TX, the company is led by Danguole Altman as President and CEO, a serial entrepreneur with an AB from Harvard and MBA from Yale; she previously founded FemPartners, raising over $15M in women's health, and worked at McKinsey and HCA.[2] The scientific foundation comes from Heather Giles, Chief Scientific Officer with 20+ years in pharma including roles at GSK and Glaxo Wellcome (PhD Pharmacology, University of London), and Terry Farmer, Director of CMC and Analytical Services with GMP manufacturing expertise from Encysive Pharmaceuticals (PhD Biochemistry, UT-Health Science Center).[2] Early traction included preclinical validation of wound pain models and pipeline advancement, culminating in a pivotal 2016 Series C round advised by Frontcourt Group, which also shaped clinical strategy and attracted family office investment.[3]
Vapogenix rides the trend toward non-opioid pain management, intensified by the opioid crisis and demand for safer alternatives amid rising chronic wound care needs from aging populations and diabetes.[1][4] Timing aligns with advances in topical delivery systems and regulatory push for localized therapies, reducing risks like addiction or GI issues from systemic drugs.[1][2] Market forces favoring it include a growing $20B+ acute pain sector, validated wound pain models enabling faster trials, and interest from veterans' health (e.g., VA intros).[3][4] By pioneering volatile anesthetic topicals, Vapogenix influences biotech ecosystems, potentially expanding to broader nervous system diseases and inspiring formulation innovations in pharma.[2][4]
Vapogenix is poised for commercialization of RAFT and AWARD post-Series C, with TAIM and preclinical assets like VPX-638 (Phase 2 pain trials via MD Anderson) driving pipeline expansion.[3][4] Trends like AI-accelerated drug reformulation and non-opioid mandates will accelerate adoption, especially in outpatient and wound care settings. Its influence may evolve through M&A (as managed in 2016) or partnerships with big pharma, solidifying a new analgesic class amid biotech's shift to precision pain relief—transforming how we target "pain in one place" without dosing the whole body.[1][3]
Vapogenix has raised $19.8M across 4 funding rounds. Most recently, it raised $1.5M Grant in November 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 11, 2020 | $1.5M Grant | National Institute OF Arthritis And Musculoskeletal And Skin Diseases | — | Announced |
| Dec 8, 2016 | $8.2M Series C | — | Pamoja Capital | Announced |
| Mar 6, 2015 | $5.1M Series B | Green Park & Golf Ventures, Pamoja Capital | — | Announced |
| Dec 1, 2013 | $5M Series B | — | Vitalize Venture Group | Announced |